UMN Pharma Inc. announced consolidated earnings results for the first nine months ended September 30, 2016. For the period, the company reported net sales of JPY 64 million against JPY 70 million a year ago. Operating loss was JPY 2,777 million against JPY 2,959 million a year ago. Loss attributable to owners of parent was JPY 2,728 million against JPY 3,074 million a year ago. Net loss per share was JPY 273.01 against JPY 321.28 a year ago. Loss before income taxes and minority interests was JPY 2,977,973,000 against JPY 3,075,559,000 a year ago. Net cash used in operating activities was JPY 1,633,095,000 against JPY 2,884,899,000 a year ago. Purchase of property, plant and equipment was JPY 1,843,413,000 against JPY 254,752,000 a year ago. Purchase of intangible assets was JPY 110,000 against JPY 2,600,000 a year ago.

The company provided earnings guidance for the year ending March 31, 2016. For the year, the company expects net sales of JPY 84 million, operating loss of JPY 3,391 million, net loss attributable to owners of the parent of JPY 3,451 million or per share of JPY 342.35.